News

Led by Professor James Brenton, this project explored the immune system and its potential to transform ovarian cancer treatments by learning more about high-grade serous ovarian cancer (HGSOC) tumours. 

Target Ovarian Cancer’s Research Manager, Emma Dennett, writes about the importance of publications and how they can be used as an early indication of the impact of our ovarian cancer research.

Led by Professor Charlie Gourley and Dr Robb Hollis, this project set out to understand more about the biology of low grade serous ovarian cancer in order to find new treatment options. 

Olaparib (Lynparza®) will be available long term on the NHS in England, Northern Ireland and Wales, from the second line of ovarian cancer treatment.

Target Ovarian Cancer's Senior Healthcare Engagement Officer, Amy Schofield, writes about the recent Public Care and Public Health conference in May 2023.

Caitlin's sharing her mum's story to raise awareness of ovarian cancer symptoms in the hope that others may recognise them in themselves or others.

A new research project awarded funding from Target Ovarian Cancer is exploring immunotherapy for high grade serous ovarian cancer.

Ever since my mum was diagnosed with ovarian cancer, I've been in contact with Target Ovarian Cancer. I found out about Run11 online and quickly created my own squad and fundraiser to support the charity and raise money for much needed research. 

Progress in ovarian cancer is possible, if urgent action is taken. That’s why the announcement of a new study to pilot use of an advanced blood test for ovarian cancer is encouraging for the ovarian cancer community.  

Led by Professor Richard Edmondson, this project set out to define the DNA damage response defects in high grade serous ovarian cancer (HGSOC) to predict patients' response to chemotherapy and the likelihood of recurrence.

For too long women have been left behind when it comes to health equity. We know that too often women’s pain and discomfort has not been taken seriously.